Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one
2. Ebc-46
1. Ebc-46
2. Ebi-46
3. Tigilanol Tiglate [usan]
4. 943001-56-7
5. R1zjt87990
6. 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tiglian-3-one
7. (4s,5s,6r,7s,8r,9r,10s,11r,12r,13s,14r)-12-(2e)-2-methyl-2-enoatyl-13((2s)-2-methylbutyroyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one
8. Unii-r1zjt87990
9. Tigilanol Tiglate [mi]
10. Tigilanol Tiglate (usan/inn)
11. Tigilanol Tiglate [inn]
12. Chembl3989916
13. Dtxsid601029530
14. Tigilanol Tiglate [who-dd]
15. D11191
16. (1ar,1br,1cs,2ar,3s,3as,6as,6br,7r,8r,8as)-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-4-oxo-1,1a,1b,1c,2a,3,3a,4,6a,6b,7,8-dodecahydro-8ah-cyclopropa(5',6')benzo(1',2':7,8)azuleno(5,6-b)oxirene-8,8a-diyl 8a-((2s)-2-methylbutanoate) 8-((2e)-2-methylbut-2-enoate)
Molecular Weight | 562.6 g/mol |
---|---|
Molecular Formula | C30H42O10 |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 8 |
Exact Mass | 562.27779753 g/mol |
Monoisotopic Mass | 562.27779753 g/mol |
Topological Polar Surface Area | 163 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 1220 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 12 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of non-resectable, non-metastatic (WHO staging) subcutaneous mast cell tumours located at or distal to the elbow or the hock, and non-resectable, non metastatic cutaneous mast cell tumours in dogs.
QL01XX
ABOUT THIS PAGE
11
PharmaCompass offers a list of Tigilanol Tiglate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tigilanol Tiglate manufacturer or Tigilanol Tiglate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tigilanol Tiglate manufacturer or Tigilanol Tiglate supplier.
PharmaCompass also assists you with knowing the Tigilanol Tiglate API Price utilized in the formulation of products. Tigilanol Tiglate API Price is not always fixed or binding as the Tigilanol Tiglate Price is obtained through a variety of data sources. The Tigilanol Tiglate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tigilanol Tiglate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tigilanol Tiglate, including repackagers and relabelers. The FDA regulates Tigilanol Tiglate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tigilanol Tiglate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tigilanol Tiglate supplier is an individual or a company that provides Tigilanol Tiglate active pharmaceutical ingredient (API) or Tigilanol Tiglate finished formulations upon request. The Tigilanol Tiglate suppliers may include Tigilanol Tiglate API manufacturers, exporters, distributors and traders.
click here to find a list of Tigilanol Tiglate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tigilanol Tiglate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tigilanol Tiglate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tigilanol Tiglate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tigilanol Tiglate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tigilanol Tiglate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tigilanol Tiglate suppliers with NDC on PharmaCompass.
Tigilanol Tiglate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tigilanol Tiglate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tigilanol Tiglate GMP manufacturer or Tigilanol Tiglate GMP API supplier for your needs.
A Tigilanol Tiglate CoA (Certificate of Analysis) is a formal document that attests to Tigilanol Tiglate's compliance with Tigilanol Tiglate specifications and serves as a tool for batch-level quality control.
Tigilanol Tiglate CoA mostly includes findings from lab analyses of a specific batch. For each Tigilanol Tiglate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tigilanol Tiglate may be tested according to a variety of international standards, such as European Pharmacopoeia (Tigilanol Tiglate EP), Tigilanol Tiglate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tigilanol Tiglate USP).